Cartesian Therapeutics RNAC
NASDAQ RNAC
$6.20 -0.20 (-3.20%)
As of: Oct 23, 2026 · 2:03 PM EDT

Cartesian Therapeutics (RNAC) EV to EBITDA (2022)

Updated

Cartesian Therapeutics' (RNAC) EV to EBITDA came in at 319.34 for Q4 2022, up 23.5% from the prior quarter.

Analysis

Cartesian Therapeutics (RNAC) EV to EBITDA (2022) Analysis & Trends

Since Q1 2022, Cartesian Therapeutics has reported EV to EBITDA for 4 quarters.

  • According to Business Quant data, EV to EBITDA for the three prior quarters was 258.50 (Q3 2022), 207.95 (Q2 2022) and 303.61 (Q1 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,129.67 Bn 1,098.26 Bn 19.71 Bn
2 Johnson & Johnson 634.09 Bn 553.95 Bn 17.30 Bn
3 AbbVie 505.39 Bn 478.51 Bn 12.70 Bn
4 Merck 357.99 Bn 312.37 Bn 12.21 Bn
5 Novartis Ag 290.73 Bn 254.72 Bn 11.24 Bn
6 Astrazeneca 264.96 Bn 238.64 Bn 12.86 Bn
7 Amgen 237.91 Bn 193.31 Bn 7.24 Bn
8 Gilead Sciences 194.88 Bn 169.07 Bn 6.22 Bn
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn
10 Cartesian Therapeutics 182.84 Mn -351.93 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 294.46
Sep 30, 2022 247.94
Jun 30, 2022 199.72
Mar 31, 2022 281.80
API Access

Cartesian Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=RNAC&period=max&api_key=YOUR_API_KEY